IINNW: AI-Bewertung 42/100 — AI-Analyse (Apr 2026)

Inspira Technologies Oxy B.H.N. Ltd. is a medical device company focused on developing respiratory support technology. Their lead product, ART, aims to provide an alternative to invasive mechanical ventilation for respiratory failure.

Eckdaten: AI Score: 42/100 Sektor: Healthcare

Unternehmensueberblick

Kurzfassung:

Inspira Technologies Oxy B.H.N. Ltd. develops the ART system, a minimally invasive respiratory support technology designed as an alternative to mechanical ventilation. Targeting respiratory failure treatment, the company operates within the medical device sector, focusing on improving patient outcomes and reducing the reliance on invasive procedures.

Was macht IINNW?

Inspira Technologies Oxy B.H.N. Ltd., established in 2018 and based in Ra'annana, Israel, is a specialty medical device company focused on innovating respiratory support technologies. Originally named Insense Medical Ltd., the company rebranded in July 2020 to reflect its focus on respiratory solutions. The company's core mission is to develop and market advanced medical devices that can provide alternatives to invasive mechanical ventilation (MV) for patients suffering from respiratory failure. Their lead product, the augmented respiration technology system (ART), is a respiratory support system designed to elevate and stabilize declining oxygen saturation levels. The ART system utilizes a minimally invasive, portable dual lumen cannula inserted into the jugular vein. This cannula facilitates extra-corporeal direct blood oxygenation, aiming to improve patient outcomes while reducing the risks associated with traditional mechanical ventilation. The ART system is designed to be more patient-friendly and less resource-intensive than existing MV methods. Inspira Technologies is currently focused on securing regulatory approvals and establishing manufacturing and distribution partnerships to commercialize the ART system globally. The company's strategy involves targeting hospitals and medical centers that treat patients with acute respiratory distress syndrome (ARDS) and other respiratory conditions. Inspira Technologies operates with a team of 37 employees, focusing on research, development, manufacturing, and marketing of its respiratory support technology.

Was ist die Investmentthese fuer IINNW?

Inspira Technologies presents a focused investment opportunity within the medical device sector, centered around its ART system. The ART system, designed as an alternative to invasive mechanical ventilation, addresses a critical need in respiratory care. The company's potential lies in securing regulatory approvals and successful commercialization of the ART system. Key value drivers include the system's potential to reduce the risks and costs associated with traditional mechanical ventilation, and its ability to improve patient outcomes. The company's small size and limited operating history present risks, but successful market penetration could drive significant revenue growth. The company's gross margin is 0.7% and profit margin is -2213.8%.

In welcher Branche ist IINNW taetig?

Inspira Technologies operates within the medical device industry, specifically targeting the respiratory care market. The industry is characterized by continuous innovation and demand for less invasive and more effective treatment options. The mechanical ventilation market is substantial, driven by the prevalence of respiratory diseases and conditions like ARDS. Inspira Technologies aims to disrupt this market with its ART system, offering a potential alternative to traditional invasive methods. Competitors in this space include companies developing similar respiratory support technologies and established manufacturers of mechanical ventilators. The industry is subject to stringent regulatory requirements and clinical validation processes.

Medical - Devices

Healthcare

Welche Wachstumschancen hat IINNW?

Expansion into New Therapeutic Areas: Inspira Technologies can explore expanding the application of its ART system beyond its initial target of ARDS patients. This could involve adapting the technology for use in treating other respiratory conditions, such as chronic obstructive pulmonary disease (COPD) or pneumonia. Expanding the therapeutic applications could significantly increase the addressable market for the ART system. The timeline for this expansion would depend on the results of clinical trials and regulatory approvals for these new indications. This strategy leverages the core technology of the ART system to address a broader range of respiratory ailments.
Geographic Market Expansion: Inspira Technologies has the opportunity to expand its market reach beyond its initial target markets. This could involve entering new regions such as Europe, Asia, and Latin America. Each of these markets presents unique regulatory and market access challenges, but also significant growth potential. The timeline for geographic expansion would depend on securing regulatory approvals in each region and establishing distribution partnerships. Successfully expanding geographically would diversify the company's revenue streams and reduce its reliance on any single market.
Strategic Partnerships and Collaborations: Inspira Technologies can pursue strategic partnerships and collaborations with other companies in the healthcare industry. This could involve partnering with medical device manufacturers, pharmaceutical companies, or healthcare providers. These partnerships could provide access to new technologies, distribution channels, and clinical expertise. The timeline for establishing these partnerships would depend on identifying suitable partners and negotiating mutually beneficial agreements. Strategic partnerships could accelerate the development and commercialization of the ART system and other respiratory support technologies.
Development of Next-Generation Respiratory Support Technologies: Inspira Technologies can invest in the research and development of next-generation respiratory support technologies. This could involve developing new versions of the ART system with improved features or exploring entirely new approaches to respiratory care. Investing in R&D would allow the company to maintain its competitive edge and capture new market opportunities. The timeline for developing these new technologies would depend on the complexity of the research and development process. Successful innovation could lead to new revenue streams and increased market share.
Focus on Home Healthcare Applications: Inspira Technologies can explore the potential for adapting its ART system for use in home healthcare settings. This would involve developing a version of the system that is suitable for use by patients in their homes, rather than in hospitals or medical centers. This could significantly expand the addressable market for the ART system, as it would allow patients to receive respiratory support in a more convenient and cost-effective setting. The timeline for developing a home healthcare version of the ART system would depend on the results of clinical trials and regulatory approvals for home use.

Inspira Technologies focuses on the development of the ART system, a respiratory support technology designed as an alternative to invasive mechanical ventilation.
The ART system utilizes a minimally invasive, portable dual lumen cannula inserted into the jugular vein for extra-corporeal direct blood oxygenation.
The company changed its name from Insense Medical Ltd. to Inspira Technologies Oxy B.H.N. Ltd. in July 2020, reflecting its focus on respiratory solutions.
Inspira Technologies is based in Ra'annana, Israel, and operates with a team of 37 employees.
The company targets hospitals and medical centers treating patients with acute respiratory distress syndrome (ARDS) and other respiratory conditions.

Welche Produkte und Dienstleistungen bietet IINNW an?

Develops the ART system, a respiratory support technology.
Focuses on providing an alternative to invasive mechanical ventilation.
Manufactures minimally invasive, portable dual lumen cannulas.
Utilizes extra-corporeal direct blood oxygenation to stabilize oxygen levels.
Targets patients with respiratory failure and ARDS.
Conducts research and development in respiratory care technologies.

Wie verdient IINNW Geld?

Develops and manufactures the ART system.
Seeks regulatory approvals for the ART system in various markets.
Commercializes the ART system through direct sales and distribution partnerships.
Generates revenue through the sale of the ART system and related consumables.

Hospitals and medical centers.
Intensive care units (ICUs).
Respiratory therapists.
Patients with respiratory failure and ARDS.

Proprietary ART system technology.
Minimally invasive approach compared to traditional mechanical ventilation.
Potential for improved patient outcomes and reduced healthcare costs.
Focus on a specific niche within the respiratory care market.

Was koennte die IINNW-Aktie steigen lassen?

Upcoming: Completion of clinical trials for the ART system.
Upcoming: Securing regulatory approvals for the ART system in key markets.
Ongoing: Establishment of manufacturing and distribution partnerships.
Ongoing: Expansion of the ART system's therapeutic applications.

Was sind die wichtigsten Risiken fuer IINNW?

Potential: Competition from established medical device companies.
Potential: Regulatory hurdles and clinical trial failures.
Potential: Technological obsolescence.
Ongoing: Dependence on securing additional funding.
Ongoing: Negative profit margin of -2213.8%.

Was sind die wichtigsten Staerken von IINNW?

Proprietary ART system technology.
Minimally invasive approach.
Potential for improved patient outcomes.
Focus on a specific niche within respiratory care.

Was sind die Schwaechen von IINNW?

Limited operating history.
Small size and limited resources.
Dependence on regulatory approvals.
High beta of 2.29 indicates high volatility.

Welche Chancen hat IINNW?

Expansion into new therapeutic areas.
Geographic market expansion.
Strategic partnerships and collaborations.
Development of next-generation technologies.

Welchen Risiken ist IINNW ausgesetzt?

Competition from established medical device companies.
Regulatory hurdles and clinical trial risks.
Technological obsolescence.
Reimbursement challenges.

Wer sind die Wettbewerber von IINNW?

Apollomics Inc. — Focuses on oncology drug development. — (APVO)
Biomerica Inc. — Develops gastrointestinal disease diagnostics. — (BMRA)
Dahan Biomedical Inc. — Unknown — (DHAI)
IN8bio Inc. — Develops gamma-delta T cell therapies. — (INAB)
Lifeward, Inc. — Unknown — (LFWD)

Key Metrics

MoonshotScore: 42/100

Company Profile

CEO: Dagi Shahar Ben-Noon
Headquarters: Raanana, IL
Employees: 37
Founded: 2021

AI Insight

AI analysis pending for IINNW

Fragen & Antworten

What does Inspira Technologies Oxy B.H.N. Ltd. do?

Inspira Technologies Oxy B.H.N. Ltd. is a medical device company specializing in the development and manufacturing of respiratory support technology. Their primary focus is on the augmented respiration technology (ART) system, which is designed as a minimally invasive alternative to traditional mechanical ventilation for patients suffering from respiratory failure. The ART system utilizes a dual lumen cannula inserted into the jugular vein to provide extra-corporeal direct blood oxygenation, aiming to improve patient outcomes and reduce the risks associated with invasive ventilation methods. The company targets hospitals and medical centers treating patients with acute respiratory distress syndrome (ARDS) and other respiratory conditions.

What do analysts say about IINNW stock?

AI analysis is currently pending for IINNW. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations cannot be provided at this time. Once the AI analysis is available, a neutral summary of analyst perspectives will be provided, focusing on key valuation metrics, growth considerations, and potential risks, without recommending buying or selling the stock. Please check back later for an update.

What are the main risks for IINNW?

Inspira Technologies faces several key risks inherent to the medical device industry and its specific business model. These include the risk of competition from larger, more established medical device companies, the potential for regulatory hurdles and clinical trial failures, and the risk of technological obsolescence. Additionally, the company faces financial risks associated with its limited operating history and dependence on securing additional funding to support its research and development efforts. The company's high beta of 2.29 indicates high volatility, reflecting the speculative nature of the stock. The company's negative profit margin of -2213.8% also poses a significant risk.

Beliebte Aktien

Alle Aktien anzeigen →